BioPharmSignal logoBioPharmSignal

Biotech News

Innate pharma to participate in the H.C. Wainwright 28th annual global investment conference

Innate Pharma (IPHA)Innate PharmaConference / presentation

Wed, 09/02/2026 - 07:00

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference:

H.C. Wainwright 28 th Annual Global Investment Conference

Dates: September 14–16, 2026

Location: New York, United States

Fireside chat:

Date: September 14, 2026

Time: 4:30 PM EDT / 10:30 PM CEST

Webcast: Access the webcast

The link to access the live webcast of the fireside chat will also be available on the Events page of the Investors section of Innate Pharma’s website. A replay will be available following the event.

Related news

IPHAInnate Pharma2026-07-22 11:17 EST

Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

View all latest news

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-09-16 19:26 EST

Innate Pharma reports first half 2026 business update and financial results

IPHAInnate Pharma2026-09-16 16:53 EST

Innate and Sobi announce partnership is now effective following completion of closing conditions

IPHAInnate Pharma2026-09-09 15:10 EST

Innate Pharma to host conference call and webcast on september 17 for first half 2026 financial results and business update

IPHAInnate Pharma2026-09-01 14:04 EST

Innate pharma to participate in the H.C. Wainwright 28th annual global investment conference

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

Stock data

Close
1.91 USD
Market cap
170.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States